




About Genmab

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged transactional research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030 Genmab's vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO®) antibody medicines.

How we Operate



Our Strengths & Differentiators

- **World-Class** antibody biology knowledge and deep insight into disease targets
- **Discovery and development engine** with proprietary technologies that allow us to build a world-class pipeline
- **In-house expertise** with solid track record of building successful strategic partnerships
- **Pipeline** of potential best-in-class and first-in-class therapies
- **Experienced, diverse** leadership team

At-a-glance

Genmab's Growing Organization & Presence

Princeton, USA

- Translational and Quantitative Sciences
- Clinical Development
- Development Operations
- U.S. Market Operations
- Corporate Functions

Copenhagen, Denmark

- Headquarters
- Translational and Quantitative Sciences
- Chemistry, Manufacturing and Controls (CMC) Operations
- Development Operations
- Quality Control Laboratory
- Corporate Functions

Utrecht, The Netherlands

- Discovery and Antibody Research
- Translational and Quantitative Sciences
- Development Operations
- Corporate Functions

Tokyo, Japan

- Development Operations
- Japan Market Operations
- Corporate Functions

Operational

8 Approved Medicines Including Genmab's Innovation

Tivdak®, first Genmab owned product on market. Genmab owned, co-developed and co-promoted in partnership with Pfizer** EPKINLY®/TEPKINLY® in partnership with AbbVie, second Genmab owned product on market DARZALEX®, RYBREXANT®, TECVAYLI® and TALVEY™ discovered and/or developed & marketed by Janssen Kesimpta® developed & marketed by Novartis TEPEZZA® developed & marketed by Horizon Therapeutics

4 Proprietary* Technologies

DuoBody® platform, HexaBody® platform, DuoHexaBody® platform & HexElect® platform


10 Proprietary* Antibody Products in Clinical Development

Tisotumab vedotin, epcoritamab, DuoBody-PD-L1x4-1BB (acasunlimab), DuoBody-CD40x4-1BB (GEN1042/BNT312), HexaBody-CD27 (GEN1053/BNT313), GEN1056 (BNT322), DuoHexaBody-CD37 (GEN3009), HexaBody-CD38 (GEN3014), DuoBody-CD3xB7H4 (GEN1047), DuoBody-EpCAMx4-1BB (GEN1059/BNT314)

>40 Cumulative INDs since 1999

Created by Genmab or with Genmab's technologies

2023 Financials (DKK)



Our Purpose

Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics

Our Vision

By 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases

Our Values

- Passion for Innovation
- Determined - being the best at what we do
- Integrity - we do the right thing
- We work as one team & respect each other

Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

Strong Pipeline of Potential 1st-in-class/Best-in-class Product Candidates

Innovative Pipeline: Genmab’s Proprietary¹ Products

Product	Developed By	Disease Indications	Most Advanced Development Phase			
			Preclinical	1	2	3
Epcoritamab	Co-development Genmab / AbbVie	Relapsed/refractory DLBCL				
		Relapsed/refractory FL				
		First line DLBCL				
		First line FL				
		B-cell NHL				
		Relapsed/refractory CLL & Richter’s Syndrome				
		Aggressive mature B-cell neoplasms in pediatric patients				
Tisotumab vedotin	Co-development Genmab / Pfizer	Cervical cancer				
		Solid tumors				
Acasunlimab (GEN1046/BNT311, DuoBody-PD-L1x4-1BB)	Co-development Genmab / BioNTech	NSCLC				
		Advanced endometrial cancer				
		Solid tumors				
DuoBody-CD40x4-1BB (GEN1042/BNT312)	Co-development Genmab / BioNTech	Solid tumors				
HexaBody-CD38 (GEN3014)	Genmab ²	Hematologic malignancies				
DuoBody-CD3xB7H4 (GEN1047)	Genmab	Solid tumors				
DuoBody-CD3xCD30 (GEN3017)	Genmab	Relapsed/refractory Hodgkin lymphoma & NHL				
HexaBody-CD27 (GEN1053/BNT313)	Co-development Genmab / BioNTech	Solid tumors				
DuoBody-EpCAMx4-1BB (GEN1059/BNT314)	Co-development Genmab / BioNTech	Solid tumors				
GEN1056 (BNT322)	Co-development Genmab / BioNTech	Solid tumors				

Programs Incorporating Genmab’s Innovation³ and Technology, ≥Phase 2 Development

Product	Technology	Discovered and/or Developed By	Disease Indications	Most Advanced Development Phase			
				Preclinical	1	2	3
Daratumumab	UltiMab	Janssen	MM				
			AL Amyloidosis				
Teprotumumab	UltiMab	Amgen	TED				
Amivantamab	DuoBody	Janssen	NSCLC				
			Advanced or metastatic gastric or esophageal cancer				
			Hepatocellular carcinoma				
			Advanced or metastatic colorectal cancer				
Teclistamab	DuoBody	Janssen	MM				
Talquetamab	DuoBody	Janssen	Relapsed/refractory MM				
Inclacumab	UltiMab	Pfizer	Vaso-occlusive crises in sickle cell disease				
Mim8	DuoBody	Novo Nordisk	Hemophilia A				
Ordesekimab (PRV-015, AMG 714)	UltiMab	Sanofi	Celiac disease				
Lu AF82422	UltiMab	Lundbeck	Multiple system atrophy				

Proprietary Technologies Allow us to Build a World-class Pipeline

DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases and hemophilia
- Multiple commercial & research collaborations

HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform

- Antibody technology that combines **DuoBody** and **HexaBody** platforms
- Creates bispecific antibodies with target mediated enhanced potency

HexElect Platform

- Antibody technology platform inspired by **HexaBody** platform
- Combines dual targeting with enhanced selectivity & potency

Executive Management

- Jan G. J. van de Winkel, Ph.D., President & CEO
- Anthony Pagano, EVP & CFO
- Judith Klimovsky, M.D., EVP & CDO
- Anthony Mancini, EVP & COO
- Tahamtan Ahmadi, M.D., Ph.D., EVP & CMO
- Birgitte Stephensen, EVP & CLO
- Christopher Cozic, EVP & CPO
- Martine J. van Vugt, Ph.D., EVP & CSO

Notes

*Tisotumab vedotin 50:50 partnership with Pfizer; epcoritamab 50:50 partnership with AbbVie; DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, HexaBody-CD27, GEN1056 and GEN1059 50:50 partnership with BioNTech; HexaBody-CD38, exclusive worldwide license and option agreement with Janssen Biotech, Inc.

**Pfizer acquired Seagen in December 2023

1Certain product candidates in development with partners, as noted

2Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.

3Products discovered and/or developed and marketed by others incorporating Genmab technology and innovation.

This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. May 2, 2024